IDO1 and metabolic dysfunction-associated steatohepatitis: Future studies employing NASH models treated with butyrate, combined with intestinal epithelium-specific AhR or IDO1 knockout mice, would be crucial to conclusively define the contribution of this host signaling axis to the effects of YCHZX-remodeled microbiota.